Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 20OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms, Germ Cell and Embryonal 1Breast Neoplasms 1

Interventions

Cisplatin 48Capecitabine 41Gemcitabine 33apatinib 32Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Nivolumab 17pembrolizumab 16Surgical Procedures, Operative 16Exercise 16Metformin 15S 1 (combination) 14camrelizumab 13Radiation 13Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11Vinorelbine 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Disulfiram × Clear all
NCT04265274 2023-10-06

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

National Cancer Institute, Slovakia

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT03950830 2023-10-04

DISGCT

National Cancer Institute, Slovakia

Phase 2 Completed
12 enrolled

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡